secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001999371-25-017369
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q3 2025 net loss widens to $32M; cash $190.1M; Tonmya launch in November
------------------------------------------------------------------------------

- Net product revenue $3.3M (up from $2.8M YoY) from Zembrace/Tosymra sales.
- Net loss $32.0M ($3.59 per share) vs $14.2M ($22.68 per share) in Q3 2024; SG&A surged to $25.7M on Tonmya launch prep.
- Cash and equivalents $190.1M (Dec 2024: $98.8M); cash runway into Q1 2027 including $34.7M from Q4 2025 equity offerings.
- Tonmya (fibromyalgia) launch in November 2025; 90 sales reps in field; WAC established; payer formulary placement for Tosymra in 2026.
- Tonix in-licensed TNX-4800 (Lyme disease mAb) and announced Phase 2 collaboration for TNX-1500 (kidney transplant).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/0001999371-25-017369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/tnxp-8k_111025.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-017369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer